Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Liberty Media Corp (LMCA), Actavis Inc (ACT), AbbVie Inc (ABBV): Investing Opportunity in 3 Profit Making Companies

Page 1 of 2

Liberty Media Corp (NASDAQ:LMCA)Charles Schwab Investment Management is one of the largest asset management companies, having assets worth $217 billion under management as on March 31, 2013. The company recently attained major positions in Liberty Media Corp (NASDAQ:LMCA)Actavis Inc (NYSE:ACT), and AbbVie Inc (NYSE:ABBV). These companies have gained attraction due to their excellent performance in the first quarter of 2013 by making acquisitions, profitable business segments, and rise in product sales.

Company making acquisitions

Liberty Media Corp (NASDAQ:LMCA) acquired more than 50% stake in Sirius XM Radio in January 2013. Sirius reported net income of $124 million, which was an increase of 15% quarter over quarter. Its revenue is heavily dependent on the automobile market, as the automobile makers have satellite radio units installed in their cars. The customer base for the company grew by 450,000 to 24.4 million customers in the first quarter of 2013, and it is expecting it to grow by an additional 1.4 million in 2013.

Sirius is expecting a tailwind in the automobile sector with a recovery of 8% Seasonal Adjusted Annual Rate to $15.3 million in the first quarter of 2013. Liberty is also planning to invest more in this segment in 2013 by developing a next generation connected car platform. The company is optimistic with the growth of the automobile sector, which will result in better revenue.

Liberty Media Corp (NASDAQ:LMCA) announced another acquisition of Charter Communications, Inc. (NASDAQ:CHTR) in March 2013, in which the company will have 27.3% stake. The stake will increase to 35% after January 2016 and will increase further to 40% thereafter. The company will pay $2.67 billion for the stake, which will include 26.9 million shares and 1.1 million warrants.

Charter Communications, Inc. (NASDAQ:CHTR) is fourth largest in the cable market in the U.S. with 4 million video subscribers and it reported a rise of 56,000 residential customers in the first quarter of 2013. Liberty was attracted towards Charter Communications, Inc. (NASDAQ:CHTR) because of its unique business plans to improve broadband service, and the growth in broadband internet remains strong as consumers demand high speed. Liberty Media Corp (NASDAQ:LMCA) is already serving some European and Latin American countries with its cable TV and broadband services, and in this deal, the company will get the direct opportunity to enter the U.S. market to serve the large customer base of Charter.

Looking at Liberty Media Corp (NASDAQ:LMCA)’s performance, the company has made good deals to secure profits in upcoming years and will observe a positive impact on revenue.

Business segment performing well

Watson Pharmaceuticals acquired Actavis Inc (NYSE:ACT) for $4.25 billion in October 2012 and took the name Actavis. After the acquisition, it became the third largest pharmaceutical company in the generic drug market in the U.S. Actavis Inc (NYSE:ACT) widened Watson’s international presence with majority sales driven by markets in the U.K., Greece, Australia, and Canada. The acquisition was successful in bringing low-cost manufacturing plants in the international market to Actavis Inc (NYSE:ACT). The company is expecting synergies of $300 million in 2014 and 2015 through research and development, growing international ventures, and low-cost manufacturing plants.

Actavis’ ‘Specialty Brand’ segment grew 9.4% year over year and generated revenue of $412 million in the first quarter of 2013. The company is expecting this segment to reach $550 million-$600 million in the second half of 2013. Actavis Inc (NYSE:ACT) is confident on the estimate due to sales of its top performing drug named ”Rapaflo”. Rapaflo is the best-selling drug for the company which is used for the treatment of enlarged prostates. Rapaflo holds 10% market share in the U.S. and the company is expecting the sales number for the drug to cross its current $100 million mark as the total prescription growth for the drug market is 32% year over year.

Page 1 of 2
Loading Comments...